Expertise in
16
conditions

Dr. Calin S. Arimie

Gastroenterology
7320 Woodlake Ave, 
West Hills, CA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
16
conditions
7320 Woodlake Ave, 
West Hills, CA 

Overview

Calin Arimie is a Gastroenterologist practicing medicine in West Hills, California.

Dr. Arimie is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Ascites, Hepatitis, Gastrointestinal Bleeding, Hemorrhoidectomy, and Gastrectomy.

Dr. Arimie is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, participating in 6 clinical trials. Dr. Arimie is currently accepting new patients.

Specialties

Gastroenterology

Licenses

Internal Medicine in CA

Board Certifications

American Board Of Internal Medicine

Fellowships

Loma Linda Medical Center , Gastroenterology , 1999 - 2002

Hospital Affiliations

UCLA West Valley Medical Center
Northridge Hospital Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Genesis Healthcare Partners
7320 Woodlake Ave, West Hills, CA 91307

Additional Areas of Focus

Dr. Arimie has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: May 13, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: April 27, 2022
Intervention Type: Drug
Study Drug: GSK2831781
Study Phase: Phase 2
View 5 Less Clinical Trials
Similar Doctors
Expertise in
23
conditions
Dr. Norah A. Terrault
Gastroenterology
Expertise in
23
conditions
Dr. Norah A. Terrault
Gastroenterology
Referral may be required

Los Angeles-Gi Liver Clinic

1510 San Pablo St Ste 200, 
Los Angeles, CA 
 (26.2 miles away)
323-442-8894
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Norah Terrault is a Gastroenterologist practicing medicine in Los Angeles, California. Dr. Terrault is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Hepatitis, Hepatitis C, Hepatitis B, Liver Transplant, and Hepato-Pancreato-Biliary Surgery.

Expertise in
15
conditions
Dr. Mark A. Pimentel
Gastroenterology
Expertise in
15
conditions
Dr. Mark A. Pimentel
Gastroenterology
Referral may be required

Cedars-Sinai Gastrointestinal (Gi) Motility

8720 Beverly Blvd, 
West Hollywood, CA 
 (16.8 miles away)
310-423-6143
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Pimentel is a Gastroenterologist practicing medicine in West Hollywood, California. Dr. Pimentel is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Irritable Bowel Syndrome (IBS), Small Bowel Bacterial Overgrowth, Diarrhea, Endoscopy, and Appendectomy.

Expertise in
42
conditions
Dr. James L. Buxbaum
Gastroenterology
Expertise in
42
conditions
Dr. James L. Buxbaum
Gastroenterology
Referral may be required

Los Angeles-Gi Liver Clinic

1510 San Pablo St Ste 200, 
Los Angeles, CA 
 (26.2 miles away)
323-442-8894
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Buxbaum is a Gastroenterologist practicing medicine in Los Angeles, California. Dr. Buxbaum is highly rated in 42 conditions, according to our data. His clinical expertise encompasses Acute Pancreatitis, Hereditary Pancreatitis, Bile Duct Obstruction, Endoscopy, and Lithotripsy.

Frequently Asked Questions about Dr. Calin S. Arimie

How do I make an appointment with Dr. Calin S. Arimie?

You can book an appointment with Dr. Calin S. Arimie by calling their office at 818-992-8505. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Calin S. Arimie a top-rated expert for Ascites?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Calin S. Arimie is classified as an Advanced expert for Ascites, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Calin S. Arimie specialize in?

While Dr. Calin S. Arimie is a Gastroenterology, they have specific expertise in Ascites, Hepatitis, and Gastrointestinal Bleeding. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Calin S. Arimie accept my insurance?

Dr. Calin S. Arimie accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 818-992-8505 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Arimie's expertise for a condition
ConditionClose
      View All 16 Advanced Conditions
      View All 58 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile